SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced results from a prospective, multicenter, single-arm study ...
– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial ...
GlobalData on MSN
FDA clears Tandem’s Control-IQ+ technology for type 2 diabetes
The US Food and Drug Administration (FDA) has cleared Tandem Diabetes Care’s Control-IQ+ technology, an automated insulin ...
Helping toddlers manage their Type 1 diabetes—typically a difficult task, due to their constant growth and development, not to mention fussiness—may now be a bit easier. The FDA has expanded its ...
Tandem Diabetes Care TNDM remained under pressure on Monday, after the company accounted for plans of a combined analysis of three trials of its Control-IQ technology. Tandem Diabetes Care’s margins ...
Hosted on MSN
Tandem Diabetes Care highlights potential for type 2 diabetes market growth with Control-IQ+
CEO John Sheridan highlighted that Tandem achieved over 20% growth for the third consecutive quarter, with record sales both in the U.S. and internationally. The company's operational focus on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback